MARTIN SHKRELI, THE former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is in custody following a securities probe.
The fraud charges against him are thought to relate to a different drug company he founded, Retrophin, and a defunct hedge fund, MSNB Capital Management, that he previously managed.
Calls to a lawyer who has represented Shkreli in the past were not immediately returned, but his arrest was confirmed today by FBI spokeswoman Kelly Langmesser.
Shkreli stirred public outrage earlier this fall when his company, Turing Pharmaceuticals, jacked the price of a drug used to treat a life-threatening infection by more than 5,000%.
Turing raised the price on Daraprim, a 62-year-old drug whose patent expired decades ago, from $13.50 to $750 per pill.
The drug is the only approved treatment for a rare parasitic infection called toxoplasmosis that mainly strikes pregnant women, cancer patients and Aids patients.
Limited competition
Shkreli said the company would cut the drug’s price. Last month, however, Turing reneged on its pledge.
Instead, the company is reducing what it charges hospitals for Daraprim by as much as 50%. Most patients’ copayments will be capped at $10 or less a month.
But insurance companies will be stuck with the bulk of the tab, potentially driving up future treatment and insurance costs.
Turing, with offices in New York and Switzerland, bought US rights to sell Daraprim in August, when it had no competition.
Daraprim is one of numerous old drugs with limited competition whose makers have raised prices sharply.
Additional reporting by Catherine Healy
To embed this post, copy the code below on your site
have your say